NT-proBNP plasma levels and echocardiographic assessment of cardiac function in patients after renal transplantation

Kardiologia Polska

Volumn 65, Issue 4, 2007, Pages 345-351

  Zbróg, Zbigniew ^a,d   Szuflet, Adam ^a   Rybińska, Agnieszka ^a   Tomaszek, Małgorzata ^a   Pierzchalska Mudyna, Teresa ^b   Piotrowski, Grzegorz ^a   Sikorska Radek, Paulina ^c   Gawor, Zenon ^a   Matych, Józef ^c  

^a M Kopernik Hospital   (Poland)

^b Medical Laboratory Eurolab   (Poland)

^c Provincial Centre of Diabetology and Metabolic Diseases   (Poland)

^d Oddzia Nefrologii WSS Im M Kopernika   (Poland)

Author keywords

Echocardiography; Immunosupression; NT proBNP; Renal transplantation

Indexed keywords

AZATHIOPRINE; BRAIN NATRIURETIC PEPTIDE; CYCLOSPORIN A; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE;

EID: 34250766269     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Dikow R, Adamczak M, Henriquez DE, et al. Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2002; 80: 5-10.
2. Locatelli F, Covic A, Chazot C, et al. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19: 1058-68.
3. Sułowicz W, Wieczorek-Surdacka E. Cardiovascular complications in patients with chronic renal failure. III Ogólnopolska Konferencja Edukacyjna. Nefrologia i Nadciśnienie Tȩtnicze 2005; Supl. S/3.
4. Januszewicz A, Paschalis-Purtak K, Puciłowska B. Peptydy natriuretyczne - co wiemy w 2005 roku? In: Wiȩcek A, Kokot F (eds). Postȩpy w nefrologii i nadciśnieniu tȩtniczym. Tom IV. Medycyna Praktyczna, Kraków 2005; 131-6.
5. Solnica B. Peptydy natriuretyczne BNP i NT-proBNP. Medycyna Praktyczna 2005; 9: 137-8.
6. Grabowski M, Or?owska-Baranowska E. Brain natriuretic peptide in the left ventricle hypertrophy. Folia Cardiol 2003; 4: 431-6.
7. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 2003; 108: 2950-3.
8. Zeng C, Wei T, Jin L, et al. Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis - dependent patients. Intern Med J 2006; 36: 552-7.
9. Taskapan MC, Ulutas O, Aksoy Y, et al. Brain natriuretic peptide and its relationship to left ventricular hypertrophy in patients on peritoneal dialysis or hemodialysis less than 3 years. Ren Fail 2006; 28: 133-9.
10. Raine AE, Margreiter R, Brunner FO, et al. Report on managment of renal failure in Europe, XXII 1991. Nefrol Dial Transplant 1992; 7 (Suppl 2): S7-35.
11. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-92.
12. London GM, Marchais SJ, Guerin AP, et al. Cardiac hypertrophy and arterial alterations in end-stage renal disease: hemodynamic factors. Kidney Int Suppl 1993; 41: S42-9.
13. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358-62.
14. Midtvedt K, Hartmann A. Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol Dial Transplant 2002; 17: 1166-9.
15. Horl WH. Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy. J Investig Med 2005; 53: 366-70.
16. Racek J, Kralova H, Trefil L, et al. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006; 103: c162-72.
17. Clerico A, Caprioli R, Del Ry S, et al. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001; 24: 24-30.